Alpha-synuclein biology
Alpha-synuclein aggregation, oligomer toxicity, prion-like spread, and the body-first vs brain-first hypothesis.
State of the art
No update yet for Alpha-synuclein biology. An update is a standalone state-of-the-art for the topic — what someone with Parkinson's needs to know about where this approach stands today.
-
Co‐ and Multi‐Pathologies in Parkinson's Disease: An International Parkinson and Movement Disorder Society Scientific Issues Committee Review
The review synthesises evidence that tau, amyloid-β, and TDP-43 do not merely coexist with alpha-synuclein but interact with it synergistically — altering its aggregation pattern, accelerating its spread through the brain, and intensifying neurodegeneration beyond what alpha-synuclein pathology alone would produce. -
Démence à corps de Lewy : voici pourquoi elle est confondue avec Parkinson et Alzheimer (et ce que ça change) - Cap Retraite
The article explains to a lay audience that LBD and Parkinson's share the same underlying pathological process — abnormal alpha-synuclein aggregates forming Lewy bodies inside neurons — which is why the two diseases overlap clinically and why treatments effective or safe in one may not be in the other.